News | November 14, 2024
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Total investment incurred for setting up the new R&D Rs 250 crore
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
Subscribe To Our Newsletter & Stay Updated
